# Alpha1-Antitrypsin Deficiency FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/alpha1-antitrypsin-deficiency

> 4 upcoming FDA catalysts in Alpha1-Antitrypsin Deficiency: fazirsiran (TAK) on Aug to Nov 2028 (topline data readout); fazirsiran (TAK) on August 2028 (primary completion); fazirsiran (TAK) on Jan to Apr 2029 (topline data readout); fazirsiran (TAK) on January 2029 (primary completion).

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug to Nov 2028 | [Fazirsiran topline data readout](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT06165341 (Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06165341)) |
| August 2028 | [Fazirsiran primary completion](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT06165341 (Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-08-26 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06165341)) |
| Jan to Apr 2029 | [Fazirsiran topline data readout](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT05677971 (Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677971)) |
| January 2029 | [Fazirsiran primary completion](https://sec-api.dev/pdufa/fazirsiran) | TAK | Alpha1-Antitrypsin Deficiency | scheduled | "NCT05677971 (Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-01-17 (ESTIMATED); Lead Sponsor Takeda." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05677971)) |

## Drugs

- [Fazirsiran](https://sec-api.dev/pdufa/fazirsiran) (TAK)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/alpha1-antitrypsin-deficiency.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Alpha1-Antitrypsin Deficiency FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/alpha1-antitrypsin-deficiency

```bibtex
@misc{secapidev_indications_alpha1_antitrypsin_deficiency_20261116,
  title        = {Alpha1-Antitrypsin Deficiency FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/alpha1-antitrypsin-deficiency}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_alpha1_antitrypsin_deficiency_20261116","title":"Alpha1-Antitrypsin Deficiency FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/alpha1-antitrypsin-deficiency","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
